Profile data is unavailable for this security.
About the company
Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The Company offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has 27 additional generic prescription drugs. In addition, the Company is engaged in the development of various proprietary drugs, including Adva-27a, K1.1 mRNA and SBFM-PL4. Adva-27a is a small chemotherapy molecule targeting pancreatic cancer. The K1.1 mRNA is developed for liver cancer. SBFM-PL4 is an anti-coronavirus compound. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). It also operates two wholly owned subsidiaries: NoraPharma Inc., which has a portfolio consisting of 50 generic prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells non-prescription over-the-counter (OTC) products.
- Revenue in USD (TTM)26.74m
- Net income in USD-4.09m
- Incorporated2006
- Employees44.00
- LocationSunshine Biopharma Inc333 Las Olas Way, Cu4 Suite 433FORT LAUDERDALE 33301United StatesUSA
- Phone+1 (954) 515-0810
- Fax+1 (514) 426-6101
- Websitehttps://www.sunshinebiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NuCana PLC (ADR) | 0.00 | -33.73m | 6.25m | 25.00 | -- | 0.5233 | -- | -- | -301.46 | -301.46 | 0.00 | 5.65 | 0.00 | -- | -- | 0.00 | -72.34 | -41.01 | -125.17 | -48.07 | -- | -- | -- | -- | -- | -- | 0.0324 | -- | -- | -- | 13.71 | -- | -21.70 | -- |
| Notable Labs Ltd | 311.00k | -12.39m | 6.28m | 16.00 | -- | 0.5439 | -- | 20.19 | -2.31 | -2.31 | 0.0622 | 1.28 | 0.0142 | -- | -- | 19,437.50 | -56.70 | -52.02 | -74.10 | -62.09 | 37.30 | 60.19 | -3,984.24 | -3,636.93 | -- | -- | 0.0271 | -- | -52.89 | -11.93 | 65.13 | -- | -50.69 | -- |
| GT Biopharma Inc | 0.00 | -9.64m | 6.34m | 2.00 | -- | 0.7643 | -- | -- | -7.04 | -7.04 | 0.00 | 3.85 | 0.00 | -- | -- | 0.00 | -64.24 | -205.36 | -90.39 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 63.62 | -- | -- | -- |
| Enzolytics Inc | 0.00 | -119.19k | 6.38m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
| Galera Therapeutics Inc | 0.00 | -45.75m | 6.38m | 7.00 | -- | -- | -- | -- | -0.9971 | -0.9971 | 0.00 | -2.48 | 0.00 | -- | -- | 0.00 | -115.30 | -83.69 | -142.79 | -97.54 | -- | -- | -- | -- | -- | -6.49 | 9.23 | -- | -- | -- | 5.05 | -- | -29.84 | -- |
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -7.35m | 6.44m | 8.00 | -- | 2.33 | -- | -- | -0.4739 | -0.4739 | 0.00 | 0.1642 | 0.00 | -- | -- | 0.00 | -96.75 | -- | -119.37 | -- | -- | -- | -- | -- | -- | -5.28 | 0.2542 | -- | -- | -- | -112.71 | -- | -- | -- |
| Paranovus Entertainment Technology Ltd | 51.46m | -42.62m | 6.46m | 80.00 | -- | 0.6048 | -- | 0.1255 | -7.16 | -7.49 | 9.89 | 1.46 | 1.18 | 59.61 | 4.15 | 643,209.90 | -91.12 | -23.19 | -119.36 | -27.21 | 4.92 | 23.09 | -77.15 | -24.25 | 3.97 | -2,465.22 | 0.00 | -- | 9.68 | 9.80 | -45.84 | -- | -21.93 | -- |
| Xenetic Biosciences Inc | 2.44m | -4.47m | 6.47m | 4.00 | -- | 0.7459 | -- | 2.65 | -2.92 | -2.92 | 1.59 | 5.63 | 0.2116 | -- | -- | 611,240.00 | -38.71 | -48.91 | -41.54 | -52.82 | -- | -- | -182.95 | -682.42 | -- | -- | 0.00 | -- | 48.80 | -- | 36.90 | -- | -- | -- |
| Energy Finders Inc | 4.06m | -2.92m | 6.52m | 46.00 | -- | -- | -- | 1.60 | -0.272 | -0.272 | 1.52 | 3.04 | -- | -- | -- | 88,304.35 | -- | -- | -- | -- | 27.45 | -- | -71.79 | -- | 0.6706 | -12.57 | 0.564 | -- | -- | -- | -- | -- | -- | -- |
| Sunshine Biopharma Inc | 26.74m | -4.09m | 6.63m | 44.00 | -- | 0.014 | -- | 0.2479 | -13.35 | -13.35 | 76.96 | 24.96 | 0.9081 | 3.13 | 11.58 | 607,722.50 | -13.88 | -101.52 | -17.99 | -137.04 | 33.15 | 35.47 | -15.29 | -165.33 | 3.23 | -- | 0.00 | -- | 454.42 | -- | 83.15 | -- | 110.99 | -- |
| Kazia Therapeutics Ltd (ADR) | 15.02k | -13.62m | 6.73m | 12.00 | -- | 0.6425 | -- | 448.04 | -0.8262 | -0.8262 | 0.0008 | 0.3518 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
| Transcode Therapeutics Inc | 0.00 | -17.06m | 6.75m | 10.00 | -- | 1.29 | -- | -- | -206.36 | -206.36 | 0.00 | 0.7893 | 0.00 | -- | -- | 0.00 | -264.82 | -133.14 | -721.90 | -181.26 | -- | -- | -- | -- | -- | -148.05 | 0.00 | -- | -- | -- | -5.59 | -- | -- | -- |
| Molecular Templates Inc | 31.76m | -18.40m | 6.85m | 62.00 | -- | 0.9522 | -- | 0.2156 | -4.36 | -4.36 | 5.98 | 1.09 | 0.6014 | -- | 19.55 | 512,306.40 | -34.83 | -51.78 | -54.80 | -73.14 | -- | -- | -57.92 | -228.33 | -- | -52.11 | 0.00 | -- | 190.10 | 33.96 | 91.24 | -- | -48.87 | -- |
| Pulmatrix Inc | 11.68m | -8.85m | 7.05m | 22.00 | -- | 0.3706 | -- | 0.6033 | -2.42 | -2.42 | 3.20 | 5.21 | 0.3517 | -- | 17.84 | 531,090.90 | -26.63 | -46.91 | -30.21 | -58.12 | -- | -- | -75.73 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
| NLS Pharmaceutics AG | 0.00 | -12.17m | 7.06m | 3.00 | -- | -- | -- | -- | -0.3188 | -0.3188 | 0.00 | -0.2724 | 0.00 | -- | -- | 0.00 | -218.86 | -272.62 | -- | -- | -- | -- | -- | -- | -- | -81.34 | -- | -- | -- | -- | 26.21 | -- | -- | -- |
Data as of Jun 25 2024. Currency figures normalised to Sunshine Biopharma Inc's reporting currency: US Dollar USD
0.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| L1 Capital Global, Inc.as of 13 Feb 2024 | 52.86k | 0.28% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 46.11k | 0.24% |
| Citadel Securities LLCas of 31 Mar 2024 | 5.51k | 0.03% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 2.86k | 0.02% |
| Jane Street Capital LLCas of 31 Mar 2024 | 876.00 | 0.01% |
| RBC Dominion Securities, Inc. (Investment Management)as of 31 Mar 2024 | 650.00 | 0.00% |
| XTX Markets LLCas of 31 Mar 2024 | 537.00 | 0.00% |
| Geode Capital Management LLCas of 31 Mar 2024 | 202.00 | 0.00% |
| Two Sigma Investments LPas of 31 Mar 2024 | 192.00 | 0.00% |
| HRT Financial LLCas of 31 Mar 2024 | 181.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 04 Jun 2024Source: FactSet Research Systems Inc.
